Minden K, et al. - Experts evaluated the Juvenile Idiopathic Arthritis (JIA) long-term outcomes in relation to the time of biological (b)DMARD initiation. In order to assess the influence of early bDMARD therapy on outcomes, patients were assigned to 3 groups based on the time from symptom onset to bDMARD start (G1: ≤2 years, G2: >2-≤5 years, G3: >5 years). Findings suggested an association of early DMARD treatment with better disease control and outcomes, thereby supporting the concept of a ‘window of opportunity’ for JIA. Compared to patients in G3, significantly lower disease activity was seen in the G1 patients. The requirement of arthroplasty was significantly less frequent in G1 patients vs G3 patients. Over time, significantly lower disease activity was seen in G1 than patients in both G2 and G3.